RT Journal Article SR Electronic T1 c-MET and HGF mRNA Expression in Hepatocellular Carcinoma: Correlation with Clinicopathological Features and Survival JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 3241 OP 3245 VO 33 IS 8 A1 CELINA SU-PING ANG A1 MARK YIPIN SUN A1 DAVID FIDEL HUITZIL-MELENDEZ A1 JOANNE FU-LOU CHOU A1 MARINELA CAPANU A1 WILLIAM JARNAGIN A1 YUMAN FONG A1 RONALD PAUL DEMATTEO A1 MICHAEL D'ANGELICA A1 PETER ALLEN A1 CHIN-TUNG CHEN A1 EILEEN MARY O'REILLY A1 MARTIN ROSS WEISER A1 GHASSAN KHALED ABOU-ALFA YR 2013 UL http://ar.iiarjournals.org/content/33/8/3241.abstract AB Background/Aim: Data on the clinicopathological features and prognostic impact of c-N-Methyl-N’-nitro-N-nitroso-guanidine HOS Transforming gene (c-MET) and hepatocyte growth factor (HGF) in hepatocellular carcinoma (HCC) are inconsistent. We assessed c-MET and HGF expression in 49 patients with early-stage HCC and correlated the results with disease characteristics and survival. Materials and Methods: Expression of c-MET and HGF mRNA in tumor (T) and non-tumor (NT) tissues was assessed. Results were correlated with patient characteristics and overall and recurrence-free survival. Results: Median relative tumor c-MET and HGF expressions were 3.23 (T/NT ratio 6.46) and 9.07 (T/NT ratio 0.77), respectively. c-MET and HGF were overexpressed in early-stage disease with favorable characteristics although there was no association with survival. Conclusion: Contrary to other studies, in our series increased tumor c-MET and HGF expressions were associated with favorable disease attributes but not with survival. The prognostic and therapeutic applications of this knowledge to HCC are under active investigation.